A bile acid-based oral carrier system delivering the GLP-1 gene maintained blood sugar control for a prolonged period from a single dose in mice, outperforming injectable semaglutide and liraglutide in preclinical efficacy.
Single oral doseOne oral dose of GLP-1 gene therapy maintained normal blood sugar in diabetic mice and outperformed both injectable semaglutide and 20 insulin injections
What the researchers found
Single oral GENE/PTCA dose induced endogenous GLP-1 and insulin production in mice. Maintained normoglycemia for a prolonged period. Higher therapeutic efficacy than FDA-approved injectable semaglutide and liraglutide in preclinical models. More effective than 20 insulin injections. High safety profile across all toxicology assessments.
Why it matters
If a single oral dose could replace daily/weekly injections for diabetes treatment, it would be transformative for the hundreds of millions of people with diabetes worldwide. Oral gene therapy that makes the body produce its own GLP-1 could bypass all the barriers of peptide drug delivery.
The numbers in context
System uses ASBT pathway for intestinal absorption. Tested in animal models of hyperglycemia.
How the study worked
Animal study. GLP-1 gene plasmid formulated with taurocholic acid-conjugated protamine sulfate and calcium phosphate (PTCA carrier). Single oral dose administered to hyperglycemic mice at different formulation doses. PK/PD endpoints: GLP-1 levels, insulin production, blood glucose, insulin sensitivity, glucose tolerance. Compared to injectable semaglutide and liraglutide. Comprehensive toxicology assessment performed.
Who was studied
Animal models of hyperglycemia
What this study cannot tell us
Mouse study — human translation is far from certain. Claims of outperforming semaglutide/liraglutide need verification in larger, independent studies. Gene therapy safety concerns (insertional mutagenesis, immune responses) not fully addressed for long-term use. Duration of effect not precisely defined. No comparison to oral semaglutide.
How to read the evidence
Rated preliminary: preclinical mouse study with impressive efficacy claims but no human data. Extraordinary claims (outperforming semaglutide) require extraordinary evidence. Gene therapy safety concerns remain.
When this study was published
Published in 2024 in ACS Nanoscience Au. Early-stage research that, if validated, could transform diabetes treatment.
The bigger picture
This represents a fundamentally different approach to GLP-1 therapy — instead of delivering the peptide itself, deliver the gene that makes the body produce its own GLP-1. If translated to humans, this could eliminate the entire injection and compliance burden of GLP-1 therapy.
Questions still open
- How long does the GLP-1 production last after a single dose in mice — days, weeks, or longer?
- What are the risks of uncontrolled GLP-1 gene expression leading to excessive hormone production?
- Can this approach be safely scaled to human clinical trials?
Common questions
Could a single pill replace daily diabetes injections?
How does GLP-1 gene therapy differ from GLP-1 drugs like semaglutide?
Read the original research
Enhancing the Therapeutic Efficacy of GLP-1 for Hyperglycemia Treatment: Overcoming Barriers of Oral Gene Therapy with Taurocholic Acid-Conjugated Protamine Sulfate and Calcium Phosphate.
ACS nanoscience Au, 4(3), 194-204
Citation
Shahriar, S M Shatil; An, Jeong Man; Surwase, Sachin S; Lee, Dong Yun; Lee, Yong-Kyu. (2024). Enhancing the Therapeutic Efficacy of GLP-1 for Hyperglycemia Treatment: Overcoming Barriers of Oral Gene Therapy with Taurocholic Acid-Conjugated Protamine Sulfate and Calcium Phosphate.. ACS nanoscience Au, 4(3), 194-204. https://doi.org/10.1021/acsnanoscienceau.3c00035